The drug company that is testing a new Alzheimer's drug, Flurizan, today signed an agreement for European distribution and marketing with a Danish pharmaceutical company.  This is an interesting development because Flurizan is one of only a handful of drugs coming down the pipeline that have made it through the final phase of FDA testing.  Results from those clinical trials are expected in June.   Reading between the lines, it seems possible to assume that the European pharma folks know something that the rest of us don't.  The reason why Flurizan is promising is that it aims to reduce the amount of toxic beta amyloid that pervades an AD brain and kills off neurons and strangles synapses.   The participants in the trial are all in the early stages of AD, which is the only time a drug like this could be effective.  Combined with the new diagnostic methods I write about in the book, which can see AD in the blood or the cerebral spinal fluid nine years before symptoms, Flurizan,  if it proves to be effective,  could have us all clamoring to be tested as early as possible.

Here is a link to an article in The Street about the pharma deal (that suggests that the Danes only have anecdotal evidence.)

Here is a discussion board for people who have family members enrolled in the clinical trial.